Eisenmenger syndrome and pulmonary arterial hypertension in adults with congenital heart disease

Current Medical Research and Opinion

Volumn 23, Issue SUPPL. 2, 2007, Pages

  Gatzoulis, Michael A ^a   Barst, Robyn ^b   Fineman, Jeffrey ^c   Galiè, Nazzareno ^d  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b NYPH   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Classification; Congenital heart disease adult; Eisenmenger syndrome; Pulmonary arterial hypertension; Treatment

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BOSENTAN; ENDOTHELIN RECEPTOR ANTAGONIST; PLACEBO; PROSTACYCLIN; SILDENAFIL; SITAXSENTAN; WARFARIN;

CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; CONGENITAL HEART DISEASE; CYANOSIS; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; ECHOCARDIOGRAPHY; EISENMENGER COMPLEX; ERYTHROCYTOSIS; EXERCISE TOLERANCE; FOLLOW UP; HEART CATHETERIZATION; HEMODYNAMICS; HUMAN; INJECTION SITE REACTION; INJECTION SITE SEPSIS; LUNG ARTERY PRESSURE; LUNG BLOOD FLOW; LUNG EMBOLISM; LUNG TRANSPLANTATION; MONOTHERAPY; PATHOPHYSIOLOGY; PHLEBOTOMY; PROGNOSIS; PULMONARY HYPERTENSION; QUALITY OF LIFE; SURVIVAL RATE;

EID: 34547430441     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X199763     Document Type: Conference Paper

References (47)

1. Brickner ME, Hillis LD, Lange RA. Congenital heart disease in adults. First of two parts. N Eng J Med 2000;342:256-63
2. Kidd L, Driscoll DJ, Gersony WM, et al. Second natural history study of congenital heart defects. Results of treatment of patients with ventricular septal defects. Circulation 1993;87 (2 Suppl):I38-51
3. Eisenmenger V. Die angeboren Defekte der Kammerscheidewand des Herzens. Z Klin Med 1897;32:1-28
4. Vongpatanasin W, Brickner ME, Hillis LD, Lange RA. The Eisenmenger syndrome in adults. Ann Intern Med 1998;128: 745-55
5. Steele PM, Fuster V, Cohen M, et al. Isolated atrial septal defect with pulmonary vascular obstructive disease - long-term follow-up and prediction of outcome after surgical correction. Circulation 1987;76:1037-42
6. Rabinovitch M, Haworth SG, Castaneda AR, et al. Lung biopsy in congenital heart disease: a morphometric approach to pulmonary vascular disease. Circulation 1978;58:1107-122
7. Haworth SG. Pulmonary hypertension in the young. Heart 2002;88:658-64
8. Diller GP, Dimopoulos K, Okonko D, et al. Exercise intolerance in adult congenital heart disease: comparative severity, correlates, and prognostic implication. Circulation 2005;112:828-35
9. Simonneau G, Galie N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004;43:5-12S
10. Wood P. The Eisenmenger syndrome or pulmonary hypertension with reversed central shunt. Br Med J 1958;46:755-62
11. Oechslin E. Eisenmenger's syndrome. In: Gatzoulis M, Webb G, Daubeney P, eds. Diagnosis and Management of Adult Congenital Heart Disease. Philadelphia: Churchill Livingstone, 2003:363-78
12. Galie N, Torbicki A, Barst R, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 2004;25:2243-78
13. Post MC, Janssens S, Van de Werf F, Budts W. Responsiveness to inhaled nitric oxide is a predictor for mid-term survival in adult patients with congenital heart defects and pulmonary arterial hypertension. Eur Heart J 2004;25:1651-6
14. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991;115:343-9
15. Daliento L, Sommerville J, Presbitero P, et al. Eisenmenger syndrome. Factors relating to deterioration and death. Eur Heart J 1998;19:1845-55
16. McLaughlin VV, Presberg KW, Doyle RL, et al. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004;126:78-92S
17. Hopkins WE, Ochoa LL, Richardson GW, Trulock EP. Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome. J Heart Lung Transplant 1996;15:100-5
18. Diller G-P, Dimopoulos K, Broberg CS, et al. Presentation, survival prospects and predictors of death in Eisenmenger syndrome: a combined retrospective and case control study. Eur Heart J 2006; 27:1737-42
19. Gibbs JSR, Broberg CS, Gatzoulis MA. Idiopathic pulmonary arterial hypertension: current state of play and new treatment modalities. Int J Card 2004;97(Suppl I):7-10
20. Dimopoulos K, Okonko DO, Diller G-P, et al. Deranged exercise ventilation patterns in adult congenital heart disease: relationship to cyanosis and survival. Circulation 2006; 2006;113:2796-802
21. Ammash N, Warnes CA. Cerebrovascular events in adult patients with cyanotic congenital heart disease. J Am Coll Cardiol 1996;28:768-72
22. Broberg CS, Bax BE, Rampling MW, et al. Blood viscosity and its relation to iron deficiency, symptoms, and exercise capacity in adults with cyanotic congenital heart disease. J Am Coll Cardiol 2006; 48:356-65
23. Perloff JK, Hart EM, Greaves SM, et al. Proximal pulmonary arterial and intrapulmonary radiologic features of Eisenmenger syndrome and primary pulmonary hypertension. Am J Cardiol 2003;92:182-7
24. Silversides CK, Granton JT, Konen E, et al. Pulmonary thrombosis in adults with Eisenmenger syndrome. J Am Coll Cardiol 2003;42:1982-7
25. Broberg C, Ujita M, Babu-Narayan S, et al. Massive pulmonary artery thrombosis with haemoptysis in adults with Eisenmenger's syndrome: a clinical dilemma. Heart 2004;90:e63
26. Broberg C, Ujita M, Bouzas B, et al. Pulmonary arterial thrombosis in Eisenmenger syndrome is associated with ventricular dysfunction, neurohormonal activation, and poorer exercise capacity. J Am Coll Cardiol 2007 (in press)
27. Rubens C, Ewert R, Halank M, et al. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest 2001;120:1562-9
28. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo- controlled study. Lancet 2001;358:1119-23
29. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346: 896-903
30. Gatzoulis MA, Rogers P, Li W, et al. Safety and tolerability of bosentan in adults with Eisenmenger physiology. Int J Cardiol 2005;98:147-51
31. Schulze-Neick I, Gilbert N, Ewert R, et al. Bosentan therapy for pulmonary arterial hypertension (PAH) in adult patients with congenital heart disease: a multicenter cooperation. Am Heart J 2005;150:716e7-12
32. Maiya S, Hislop AA, Flynn Y, Haworth SG. Response to bosentan in children wim pulmonary hypertension. Heart 2006;92:664-70
33. Apostolopoulou SC, Rammos S, Kyriakides ZS, et al. Acute endothelin A receptor antagonism improves pulmonary and systemic haemodynamics in patients with pulmonary arterial hypertension that is primary or autoimmune and related to congenital heart disease. Heart 2003;89:1221-7
34. Galie N, Beghetti M, Gatzoulis MA, et al. on behalf of the BREATHE-5 Investigators: Bosentan therapy in patients with Eisenmenger syndrome: a multi-centre, double-blind randomised placebo-controlled study. Circulation 2006; 114:48-54
35. Hoeper MM, Maier R, Tongers J, et al. Determination of cardiac output by the Fick method, thermodilution, and acetylene rebreathing in pulmonary hypertension. Am J Respir Crit Care Med 1999;160:535-41
36. Kuehne T, Yilmaz S, Schulze-Neick I, et al. Magnetic resonance imaging guided catheterisation for assessment of pulmonary vascular resistance: in vivo validation and clinical application in patients with pulmonary hypertension. Heart 2005;91;1064-9
37. Paciocco G, Martinez F, Bossone E, et al. Oxygen desaturation on the six-minute wall test and mortality in untreated primary pulmonary hypertension. Eur Respir J 2001;17:647-52
38. Galie N, Hinderliter AL, Torbicki A, et al. Effects of the oral endothelin-receptor antagonist bosentan on echocardiography and Doppler measures in patients with pulmonary arterial hypertension. J Am Coll Cardiol 2003;41:1380-6
39. Diller G-P, Gatzoulis MA. Pulmonary vascular disease in adult congenital heart disease. Circulation 2007;115:1039-50
40. Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 1999;99:1858-65
41. Mikhail GW, Prasad SK, Li W, et al. Clinical and haemodynamic effects of sildenafil in pulmonary hypertension: acute and midterm effects. Eur Heart J 2004;25:431-6
42. Humpl T, Reyes JT, Holtby H, et al. Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single-drug, open-label, pilot study. Circulation 2005;111:3274-80
43. Wilkins MR, Paul GP, Strange JW, et al. Sildenafil versus endothelin receptor antagonist for pulmonary hypertension (SERAPH) study. Am J Respir Crit Care Med 2005;171: 1292-7
44. Galiè N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353:2148-57
45. Stoica SC, McNeil KD, Perreas K, et al. Heart-lung transplantation for Eisenmenger syndrome: early and long-term results. Ann Thorac Surg 2001;72:1887-91
46. Waddell TK, Bennett L, Kennedy R, et al. Heart-lung or lung transplantation for Eisenmenger syndrome. J Heart Lung Transplant 2002;21:731-7
47. Khambadkone S, Li J, de Leval MR, et al. Basal pulmonary vascular resistance and nitric oxide responsiveness late after Fontan-type operation. Circulation 2003;107: 3204-8